CompletedNCT06258031
Psilocybin feasibility study for obsessive compulsive symptoms
About this title
Read the official source — NCT06258031Medication studyAges 20–65United KingdomOCD
Understand this study
Who was this study for?
Listed age limits: 20 years to 65 years.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: October 28, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 19
- Sponsor
- Imperial College London
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 20 Years to 65 Years
- Official registry ID
- NCT06258031
- Official title
Show the full official title
PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Imperial College London, a university.
Did this study involve medication?
Yes. The study involved medication, including Psilocybin (COMP360).
Who was this study for?
Listed age limits: 20 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination i...
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with OCD